The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...

Its health care business showed good profitability thanks to multiple sclerosis drug Mavenclad and cancer drug Erbitux, as ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Mavenclad hasn’t really got going yet in sales terms, bringing in a modest €90 million in 2018 from the 50 or so countries it has been approved in to date, albeit up from just €5 million in ...

Investing.com -- Shares of Merck KGaA surged after the company confirmed its outlook for fiscal year 2024 and revisions to its mid-term sales projections, particularly for its Life Science and ...

Those two drugs are billed as Merck 'wave 2' medicines, building on a first wave of recent launches, including PD-1 inhibitor Bavencio (avelumab), Mavenclad (cladribine) for MS and lung cancer ...

Mavenclad (cladribine) is for highly active relapsing forms of MS. The dosage schedule is unusual, with short periods of taking pills spread out over two years. This drug temporarily reduces your ...

Others are possible teratogens, such as Gilenya (fingolimod), Mayzent (siponimod), and Mavenclad (cladribine). For other DMTs, their safety for use in pregnancy remains unclear. In these cases, the ...

which is the active ingredient of the approved oral treatment Mavenclad, in relapsing multiple sclerosis (MS), showed comparable pharmacological properties to its name-brand counterpart.